Consecutively, different radiolabeled PSMA analogues were created and have recently been successfully implemented as a diagnostic imaging tool for patients with advanced prostate cancer with reported sensitivities up to 97% for PSMA compounds labeled with 68Gallium (68Ga), depending on prostate specific antigen (PSA) serum levels [7,8]. The gene discussed is FOLH1; the disease is Familial prostate cancer.